Categories Earnings, Industrials

Caterpillar turns red on disappointing Q3, slashed outlook

Shares of Caterpillar Inc. (NYSE: CAT) plunged 4% during the pre-market hours on Wednesday after the company missed market estimates in the third quarter and slashed its EPS outlook again.

Revenue for the third quarter fell 6% to $12.8 billion, well below the street target of $13.6 billion. The heavy-machinery manufacturer blamed lower-than-expected end-user demand and reduction in inventories by dealers or the lower revenues.

caterpillar Q3 2019 earnings infographic

Net income fell to $2.66 per share from $2.88 per share a year ago. Wall Street was expecting flat year-over-year EPS of $2.88 per share.

The company also slashed it outlook EPS outlook to a range of $10.90 to $11.40, compared to the earlier estimate of $12.06 to $13.06 per share.

READ: iRobot posts upbeat Q3 earnings, but stock tumbles on weaker guidance

CEO Jim Umpleby said in a statement, “In the fourth quarter, we now expect end-user demand to be flat and dealers to make further inventory reductions due to global economic uncertainty. Caterpillar’s improved lead times, along with these dealer inventory reductions, will enable us to respond quickly to positive or negative developments in the global economy in 2020.”

CAT stock has gained 5.5% in the year-to-date period.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Also Read:  [INFOGRAPHIC] Key highlights from Booking Holdings (BKNG) Q2 2020 earnings results

Most Popular

Baidu (BIDU) Q2 earnings rise unexpectedly; stock falls China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the

Applied Materials (AMAT) tops Q3 2020 targets; provides Q4 outlook

Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,

Is Altimmune (ALT) stock a buy right now?

A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies